RLM-MD-02 Diabetic Gastroparesis

A 12-week randomized, double-blind, placebo-controlled, Phase 3 study to evaluate the safety and efficacy of Relamorelin in patients with diabetic gastroparesis and vomiting at screening. Protocol rolls over into RLM-MD-03.

Product: Relamorelin (also known as RM-131) is a novel, potent and selective synthetic penta-peptide ghrelin analogue, which is being developed for the treatment of diabetic gastroparesis (DG).

Sponsor: Allergan

Principal Investigator: Dr. William Holderman